Design and synthesis of carbohydrate-based inhibitors of protein-carbohydrate interactions.

Our understanding of carbohydrate-protein interactions has significantly advanced over the past two years. In particular, a healthy amount of literature has appeared on selectins and their relevant ligands. A significant number of carbohydrate-metabolizing enzyme crystal structures have been solved which provide useful starting points for computer-assisted drug design. Some of these proteins have been implicated either directly or indirectly in playing roles in human-disease states, for example, in inflammation, in diabetes and its complications, and in microorganism-induced diseases such as influenza and cholera.

[1]  K. H. Kalk,et al.  Structure of the 70-kDa soluble lytic transglycosylase complexed with bulgecin A. Implications for the enzymatic mechanism. , 1995, Biochemistry.

[2]  G. Primofiore,et al.  Synthesis of pyrrolo[3,4-c]pyridine derivatives possessing an acid group and their in vitro and in vivo evaluation as aldose reductase inhibitors , 1996 .

[3]  E. Freire,et al.  Thermodynamics of intersubunit interactions in cholera toxin upon binding to the oligosaccharide portion of its cell surface receptor, ganglioside GM1. , 1989, Biochemistry.

[4]  E Garman,et al.  Crystal structure of Vibrio cholerae neuraminidase reveals dual lectin-like domains in addition to the catalytic domain. , 1994, Structure.

[5]  K. Moore,et al.  Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. , 1994, Acta crystallographica. Section D, Biological crystallography.

[6]  S. Crennell,et al.  Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Sixma,et al.  Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography , 1992, Nature.

[8]  S. Cusack,et al.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.

[9]  G. Whitesides,et al.  Polyacrylamides Bearing Pendant α-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions , 1996 .

[10]  Structural aspects of the allosteric inhibition of fructose-1,6-bisphosphatase by AMP: the binding of both the substrate analogue 2,5-anhydro-D-glucitol 1,6-bisphosphate and catalytic metal ions monitored by X-ray crystallography. , 1995 .

[11]  Chi‐Huey Wong,et al.  Ligand Recognition by E-Selectin: Synthesis, Inhibitory Activity and Conformational Analysis of Bivalent Sialyl Lewis x Analogs , 1995 .

[12]  G M Whitesides,et al.  Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. , 1989, Biochemistry.

[13]  G. Jacob,et al.  Glycosylation inhibitors in biology and medicine. , 1995, Current opinion in structural biology.

[14]  G. Thoma,et al.  Synthesis of a Sialyl Lewis x Mimic with Fixed Carboxylic Acid Group: Chemical Approach toward the Elucidation of the Bioactive Conformation of Sialyl Lewis x. , 1996, The Journal of organic chemistry.

[15]  G. Petsko,et al.  An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. , 1994, Biochemistry.

[16]  N. Isaacs,et al.  The catalytic domain of a bacterial lytic transglycosylase defines a novel class of lysozymes , 1995, Proteins.

[17]  V. Villeret,et al.  Crystal structure of spinach chloroplast fructose-1,6-bisphosphatase at 2.8 A resolution. , 1995, Biochemistry.

[18]  T. G. Hill,et al.  Carbohydrate materials bearing neuraminidase-resistant C-glycosides of sialic acid strongly inhibit the in vitro infectivity of influenza virus. , 1992, Journal of medicinal chemistry.

[19]  P. Oates,et al.  Aldose reductase inhibitors: recent developments. , 1993, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[20]  F. G. Prendergast,et al.  Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. , 1994, Biochemistry.

[21]  M. S. Biggers,et al.  General Preparation of 7-Substituted 4-Chromanones: Synthesis of a Potent Aldose Reductase Inhibitor , 1994 .

[22]  G M Whitesides,et al.  Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. , 1995, Journal of medicinal chemistry.

[23]  G. Air,et al.  Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction. , 1995, Journal of medicinal chemistry.

[24]  Thilo Stehle,et al.  Structure of murine polyomavirus complexed with an oligosaccharide receptor fragment , 1994, Nature.

[25]  J. Turunen,et al.  Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion. Evidence that multivalency enhances the saccharide binding to L-selectin. , 1995, European journal of biochemistry.

[26]  Kuo-Sen Huang,et al.  Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains , 1994, Nature.

[27]  L. Lasky.  Selectin-carbohydrate interactions and the initiation of the inflammatory response. , 1995, Annual review of biochemistry.

[28]  C. Bertozzi,et al.  The selectins and their ligands. , 1994, Current opinion in cell biology.

[29]  E. Garman,et al.  Purification, crystallization and preliminary crystallographic study of neuraminidase from Vibrio cholerae and Salmonella typhimurium LT2. , 1992, Journal of molecular biology.

[30]  Roger S. Holmes,et al.  Enzymology and Molecular Biology of Carbonyl Metabolism 5 , 1995, Advances in Experimental Medicine and Biology.

[31]  J. Martial,et al.  Crystal structure of cholera toxin B‐pentamer bound to receptor GM1 pentasaccharide , 1994, Protein science : a publication of the Protein Society.

[32]  F. Hayden,et al.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.

[33]  S. Crennell,et al.  The three domains of a bacterial sialidase: a beta-propeller, an immunoglobulin module and a galactose-binding jelly-roll. , 1995, Structure.

[34]  C. Bertozzi,et al.  Sulfated disaccharide inhibitors of L-selectin: deriving structural leads from a physiological selectin ligand. , 1995, Biochemistry.

[35]  G. Petsko,et al.  Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. , 1994, Biochemistry.

[36]  W G Laver,et al.  A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. , 1995, Journal of molecular biology.

[37]  M. Itzstein,et al.  Aldose reductase as a target for drug design: molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme. , 1995 .

[38]  Chi‐Huey Wong,et al.  Synthesis of Biologically Active Sialyl Lewis X Mimetics , 1995 .

[39]  David D. Manning,et al.  Selectin-Saccharide Interactions: Revealing Structure-Function Relationships with Chemical Synthesis , 1995 .

[40]  F A Quiocho,et al.  An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.

[41]  S. Casnocha,et al.  Multivalent sialyl-LeX: potent inhibitors of E-selectin-mediated cell adhesion; reagent for staining activated endothelial cells. , 1994, Glycobiology.